Date post: | 16-Apr-2017 |
Category: |
Business |
Upload: | kisaco-research |
View: | 117 times |
Download: | 2 times |
1
Curtiss HealthcareAnimal Health Asia
Hong Kong, October 2016Thomas Bigger, CEO
HealthCare A New World of Health
Curtiss Healthcare Highlights & Near Term Milestones
Founded in 2015 to commercialize research of Prof Roy Curtiss lll
Develop novel vaccines to prevent critical infectious diseases in animals & humans
Orally delivered Live Recombinant Attenuated Salmonella Vector (RASV) Vaccines
$1.4M in seed capital raised to date
>100 issued patents licensed exclusively from 3 universities
Series A to raise $12 - $15M to advance 5 - 6 vaccines
In advanced discussions with several prospective AgPharma partners
2HealthCare A New World of Health
Exclusive Licenses Consolidated IP from 3 World Class Universities
Washington Arizona State University
University University of Florida
3HealthCare A New World of Health
What is Unique About Curtiss Healthcare’s Offering
Unique Technology: Disruptive vaccine technology Single vector affords multiple pathogen protection Auto lysing or self destruction (minimizes host &
environmental effects) Vector proven safe in multiple species
Meets Market Needs: Avoids/address concerns about antibiotic resistance Delivered orally Utilizes conventional manufacturing process Economic benefit to producers
4
Curtiss’ Technology Initially Focused on Improving Food Safety and Food Quality
Why Food Safety and Food Quality (FS/FQ)
· Increased expectations for food safety & antibiotic free products from major buyers and end consumers
· Middle class growth expanding globally with similar food quality demands in established & growing markets
· FS/FQ is key pillar for growth in all 3 leading food producing animal franchises
· Majority of unmet targets are bacterial, where industry’s portfolio is deficient while antibiotic use being curtailed
5 HealthCare A New World of Health
Trader Joe's urged to drop meat from animals raised with antibiotics
Publicized “No Antibiotics Ever” campaign in 2015
McDonalds to cut use of antibiotics in chicken
Value of Controlling Human Food-Borne Illnesses
Food producing animals contribute more than $300 billion in revenues to the U.S. economy
Food-borne illnesses cost U.S. economy $15 billion annually*CDC estimates there are 48 million food-borne infections in the
U.S. each yearLeading approaches to combat food-borne illnesses
Improving food handling techniques, personal hygiene and sanitary engineering
Vaccines>$5 billion currently spent to control bacterial infections in
food producing animals
6* USDA estimates
HealthCare A New World of Health
Why Vaccines Are So Important for Agricultural Animals?
Bacterial infections will always be present in agriculture
Prevent many different bacterial infections and reduce the need for broad antibiotic use
Convenient and easy to use
Prevent development of antimicrobial resistance
Economic benefit to producers
7HealthCare A New World of Health
Why Use Salmonella as a Vaccine Vector?
Highly efficient invader in the gastro-intestinal tissues of target species
Vector attaches to mucosal lymphoid tissues and colonizes internal lymph nodes, liver & spleen
Produces robust immune stimulation and long-term protective immunity
Easily manipulated genetically which facilitates vaccine design
Curtiss Healthcare has a broad IP position using Salmonella in vaccines in animals and humans
8HealthCare A New World of Health
Why Is Curtiss Healthcare’s RASV Platform Needed Today?
9HealthCare A New World of Health
· Current vaccines not ideal for initial target infections
· Current treatment for target infections is intensive use of antibiotics
· Market and regulatory pressure to curtail or eliminate use of antibiotics
· Convenient oral delivery (in feeds, water or by spray)
· Maximum immunity with minimal reactivity
· Self-destruct, eliminating shedding and spreading
· Provides cost effective return for producer
Curtiss Is Targeting Key Markets in FS & FQ - Initial Products in Avian & Swine
10HealthCare A New World of Health
Avian products to reduce food-borne pathogens and improve bird health and growth C. perfringens (Necrotic Enteritis) Campylobacter
Salmonella
E. coli
Swine disease is often subclinical and leads to productivity loss and increased costs Helicobacter
Lawsonia
E. coli
Initial Avian and Swine FS & FQ Products Represent Substantial Revenue Potential Avian (birds) products to reduce food-borne
pathogens and improve bird health and growth C. perfringens (Necrotic Enteritis) Campylobacter
Salmonella
E. coli
Swine (pigs) disease is often subclinical and leads to productivity loss and increased costs Helicobacter
Lawsonia
E. coli
Total Peak U.S. Sales Potential of 6 Initial Programs:11
HealthCare A New World of Health
U.S. Peak Annual Sales*
$35 million
$60 million
$40 million
$20 million
$35 million
$45 million
$10 million
$235 million
* U.S. product sales estimates by Prospective Pharma Partner
· Necrotic enteritis (NE) disease is widespread in broilers, causes diarrhea, high morbidity and mortality 10 - 40%
· Clostrium perfringens is a gram-positive, spore-forming, rapidly growing anaerobe
· Sub-clinical form is most prevalent cause of reduced growth performance
· Affects chickens beginning soon after hatch until death· NE is expected to increase with elimination/reduction of
antibiotic use
Curtiss Healthcare’s Most Advanced Product Targets Necrotic Enteritis caused by C. perfringens
12HealthCare A New World of Health
Healthy Chicks
Proof of Efficacy in Necrotic EnteritisSalmonella enterica / Clostridium perfringens
Vaccine #2:
In consecutive studies using a single oral vaccination of chicks on the day of hatch results indicate:
Statistically significant protection from mortality; in a “real world” model, including a C. perfringens - coccidia pre-challenge
Statistically significant protection from development of lesions from C. perfringens
A dose dependent effect in protection, supporting the studies
Improved body weights and feed conversion ratios - comparable to the standard antibiotic treatment13
HealthCare A New World of Health
Business Strategy Initial opportunities for Proof of Concept for RASV
technology in avian market (and then porcine, bovine & companion animals)
Partner initial products to generate cash flow
Identify and develop human Salmonella-based vaccines for infectious diseases (i.e. Influenza, E. coli, Clostridium difficile)
Utilize Salmonella-based vectors for delivery of immunotherapy treatments for Cancer (preliminary data available)
Exploration funded by multiple grants through Dr. Curtiss’s lab at University of Florida
14HealthCare A New World of Health
Management Team Thomas Bigger - CEO/President/Co-Founder
Experienced biotechnology executive Decades of infectious disease experience
Roy C. Curtiss lll - CSO/Co-Founder World class scientist – National Academy of Sciences member, life-
time member American Society of Microbiology Recognized world expert “has played a seminal role in the Salmonella
Vaccine field for at least 30 years” Substantial NIH and Gates funding Decades of experience in developing live vaccines
Dennis Molnar - CFO/VP Commercial Development Experienced biotechnology executive Decades of infectious disease experience
Robert Nordgren – Technical Research Advisor Experienced animal health executive 32 years of experience in developing vaccines for animal health
15HealthCare A New World of Health
Funding the Future for Curtiss Healthcare
3 Phase Funding Plan: Seed funding = $1.4 - $1.7 million
Funds lab start-up & lead program hand-off to partner – C. perfringens
Series A over next 3 - 4 years = $12 - $15 million
Funds next 4 - 5 avian & swine program development to milestones
Milestones & grants >4 years provide sustained funding (+cash flow)
Development in swine/cattle and emerging human programs funded
16HealthCare A New World of Health